Robin Carhart-Harris

Last updated
Robin Carhart-Harris
190723 Robin Carhart-Harris, Centre for Psychedelic Research meeting (cropped).jpg
Carhart-Harris in 2019
Born (1980-08-31) 31 August 1980 (age 43)
Durham, England, UK
Alma mater
Known for Psychedelic therapy
Scientific career
Fields Psychopharmacology
Institutions
Doctoral advisor Sue Wilson
Website Official website OOjs UI icon edit-ltr-progressive.svg

Robin Lester Carhart-Harris (born 31 August 1980) is a British psychopharmacologist who is Ralph Metzner Distinguished Professor in the Department of Neurology at the University of California, San Francisco. Previously, he founded and was Head of the Centre for Psychedelic Research at Imperial College London. [1]

Contents

He is noted for brain imaging studies of psychedelic and psychoactive drugs such as LSD, psilocybin, MDMA, and DMT, and research into their therapeutic use in treating psychiatric disorders such as depression. [2] [3] [4] In 2020, The Times named him one of the world's top 31 medical scientists. [5] The following year, he was included in TIME magazine's "100 Next" list of 100 notable people "poised to make history". [6]

Early life and career

Carhart-Harris was born in Durham, grew up in Bournemouth, [7] and took a BSc in Applied Psychology and Computing at Bournemouth University from 2001 to 2004. [8] The following year, he moved to Brunel University and earned an MSc in Psychoanalysis and Contemporary Society. [9] Between 2005 and 2009, he took his doctorate, focused on the psychopharmacology of the serotonin system, supervised by Sue Wilson and Marcus Munafo at the University of Bristol. [1] [10] [11] Carhart-Harris joined David Nutt at Imperial College London in 2008, [12] and they have been regular collaborators on the use of psychoactive drugs in treating a variety of psychiatric disorders. [7] [13]

In 2014, while at Imperial, Carhart-Harris became the first scientist in 40 years to test the effects of LSD legally on human volunteers. [7] In 2016, his team published promising findings from "the world's first modern research trial investigating the impact of psilocybin" on 19 patients with treatment-resistant depression. [14] [15] The study showed a decrease in symptoms of depression for at least three weeks. [16] Three years later, he founded the Centre for Psychedelic Research at Imperial College, the first of its kind in the world, and remained its head for the next two years. [9] [17] In 2021, Carhart-Harris relocated to the United States when he was appointed Ralph Metzner Distinguished Professor and Director of the Neuroscape Psychedelics Division in the Department of Neurology at the University of California, San Francisco. [1] [18]

Research interests

Scientific study of psychedelic drugs was effectively halted in the early 1970s when the 1970 US Controlled Substances Act and 1971 UN Convention on Psychotropic Substances made substances such as LSD illegal across much of the world. [19] Along with other academic researchers such as Roland R. Griffiths and Matthew W. Johnson of Johns Hopkins University, Robin Carhart-Harris is one of a growing number of scientists credited with rekindling interest in the field. [20] [21]

Robin Carhart-Harris (standing) prepares an fMRI brain scan of writer Michael Pollan at Imperial College London in 2019 190603 Functional magnetic resonance imaging at the Imperial Centre for Psychedelic Research.jpg
Robin Carhart-Harris (standing) prepares an fMRI brain scan of writer Michael Pollan at Imperial College London in 2019

Carhart-Harris is noted for brain imaging studies and clinical trials of drugs such as LSD, psilocybin (the psychoactive compound found in magic mushrooms), MDMA (ecstasy), and DMT (the psychoactive substance in ayahuasca) for treating psychiatric disorders, [1] [7] particularly treatment-resistant depression. [22] [23] [24] His research has also compared the effectiveness of psychedelic drugs against conventional SSRI drug treatments for depression. [25] [26] Carhart-Harris believes psychedelics could be useful in treating other mental disorders, such as addiction and obsessive–compulsive disorder (OCD). [27]

He has predicted that this type of research will "cross over into the mental health mainstream... as support for the use of psychedelics in medicine continues to gain momentum". [28] [29]

Carhart-Harris believes psychedelics work by "breaking down habits of mind and brain and behavior", [30] causing "a cascade of neurobiological changes that manifest at multiple scales and ultimately culminate in the relaxation of high-level beliefs". [31] These changes include heightened neuroplasticity and disruption of the default mode network (responsible for background brain activities such as mind wandering and daydreaming). [31] However, the issue remains controversial and there is no firm scientific consensus on how psychedelics achieve their effects. [30]

Awards

In 2008, Carhart-Harris earned the Bristol-Cardiff Young Neuroscientist Award. [8] In 2015, he gained the British Association for Psychopharmacology Award. [32] He won the 2018 Association for Behavior Analysis International B F Skinner award. [8] In 2020, The Times named him one of the world's top 31 medical scientists. [5] TIME magazine included him in its "100 Next" list of 100 people likely to make history in 2021. [6] In 2023, the Vox news and opinion website named him one of its "Future Perfect 50", a list of "visionaries who have made an impact in their fields to improve lives now and in the future". [33]

Other activities

Carhart-Harris works as a scientific adviser to numerous pharmaceutical companies. [34] [35] [36]

Personal life

Carhart-Harris is married with two children. [8] [37]

Selected publications

Accessible articles and op-ed pieces

Academic papers

Related Research Articles

<span class="mw-page-title-main">LSD</span> Hallucinogenic drug

Lysergic acid diethylamide, commonly known as LSD, and known colloquially as acid or lucy is a potent psychedelic drug. Effects typically include intensified thoughts, emotions, and sensory perception. At sufficiently high dosages LSD manifests primarily mental, visual, and auditory hallucinations. Dilated pupils, increased blood pressure, and increased body temperature are typical. Effects typically begin within half an hour and can last for up to 20 hours. LSD is also capable of causing mystical experiences and ego dissolution. It is used mainly as a recreational drug or for spiritual reasons. LSD is both the prototypical psychedelic and one of the "classical" psychedelics, being the psychedelic with the greatest scientific and cultural significance. LSD is synthesized as a solid compound, typically in the form of a powder or a crystalline material. This solid LSD is then dissolved in a liquid solvent, such as ethanol or distilled water, to create a solution. The liquid serves as a carrier for the LSD, allowing for accurate dosage and administration onto small pieces of blotter paper called tabs. LSD is typically either swallowed or held under the tongue. In pure form, LSD is clear or white in color, has no smell, and is crystalline. It breaks down with exposure to ultraviolet light.

<span class="mw-page-title-main">Psilocybin</span> Chemical compound found in some species of mushrooms

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of lysergic acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT). In general, the effects include euphoria, visual and mental hallucinations, changes in perception, distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and an apparent expansion of consciousness. Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively. This article makes use of the narrower classical definition of psychedelics. Classic psychedelics generally cause specific psychological, visual, and auditory changes, and oftentimes a substantially altered state of consciousness. They have had the largest influence on science and culture, and include mescaline, LSD, psilocybin, and DMT.

<span class="mw-page-title-main">Entheogen</span> Psychoactive substances that induce spiritual experiences

Entheogens are psychoactive substances that induce alterations in perception, mood, consciousness, cognition, or behavior for the purposes of engendering spiritual development or otherwise in sacred contexts. Anthropological study has established that entheogens are used for religious, magical, shamanic, or spiritual purposes in many parts of the world. Entheogens have traditionally been used to supplement many diverse practices geared towards achieving transcendence, including divination, meditation, yoga, sensory deprivation, asceticism, prayer, trance, rituals, chanting, imitation of sounds, hymns like peyote songs, drumming, and ecstatic dance. The psychedelic experience is often compared to non-ordinary forms of consciousness such as those experienced in meditation, near-death experiences, and mystical experiences. Ego dissolution is often described as a key feature of the psychedelic experience.

<span class="mw-page-title-main">Psilocybin mushroom</span> Mushrooms containing psychoactive indole alkaloids

Psilocybin mushrooms, commonly known as magic mushrooms or shrooms, are a polyphyletic informal group of fungi that contain psilocybin, which turns into psilocin upon ingestion. Biological genera containing psilocybin mushrooms include Psilocybe, Panaeolus, Inocybe, Pluteus, Gymnopilus, and Pholiotina.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

A psychedelic experience is a temporary altered state of consciousness induced by the consumption of a psychedelic substance. For example, an acid trip is a psychedelic experience brought on by the use of LSD, while a mushroom trip is a psychedelic experience brought on by the use of psilocybin. Psychedelic experiences feature alterations in normal perception such as visual distortions and a subjective loss of self-identity, sometimes interpreted as mystical experiences. Psychedelic experiences lack predictability, as they can range from being highly pleasurable to frightening. The outcome of a psychedelic experience is heavily influenced by the person's mood, personality, expectations, and environment.

<span class="mw-page-title-main">Heffter Research Institute</span> Nonprofit organization

The Heffter Research Institute is a 501(c)(3) nonprofit organization that promotes research with classic hallucinogens and psychedelics, predominantly psilocybin, to contribute to a greater understanding of the mind and to alleviate suffering. Founded in 1993 as a virtual institute, Heffter primarily funds academic and clinical scientists and made more than $3.1 million in grants between 2011 and 2014. Heffter's recent clinical studies have focused on psilocybin-assisted treatment for end-of-life anxiety and depression in cancer patients, as well as alcohol and nicotine addiction.

<span class="mw-page-title-main">Marsh Chapel Experiment</span> 1962 psychological research study on religious experiences of psilocybin users

The Marsh Chapel Experiment, also called the "Good Friday Experiment", was an experiment conducted on Good Friday, April 20, 1962 at Boston University's Marsh Chapel. Walter N. Pahnke, a graduate student in theology at Harvard Divinity School, designed the experiment under the supervision of Timothy Leary, Richard Alpert, and the Harvard Psilocybin Project. Pahnke's experiment investigated whether psilocybin would act as a reliable entheogen in religiously predisposed subjects.

The Beckley Foundation is a UK-based think tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

Amanda Claire Marian Charteris, Countess of Wemyss and March, also known as Amanda Feilding, is an English drug policy reformer, lobbyist, and research coordinator. In 1998, she founded the Foundation to Further Consciousness, later renamed to the Beckley Foundation, a charitable trust which initiates, directs, and supports neuroscientific and clinical research into the effects of psychoactive substances on the brain and cognition. She has also co-authored over 50 papers published in peer-reviewed journals, according to the Foundation. The central aim of her research is to investigate new avenues of treatment for such mental illnesses as depression, anxiety, and addiction, as well as to explore methods of enhancing well-being and creativity.

Hallucinogens are a large and diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mood, and perception as well as other changes. Most hallucinogens can be categorized as either being psychedelics, dissociatives, or deliriants.

<span class="mw-page-title-main">David Nutt</span> English neuropsychopharmacologist

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs. Until 2009, he was a professor at the University of Bristol heading their Psychopharmacology Unit. Since then he has been the Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Nutt was a member of the Committee on Safety of Medicines, and was President of the European College of Neuropsychopharmacology.

Psychedelic microdosing involves consuming sub-threshold doses (microdoses) of serotonergic psychedelic drugs like LSD and psilocybin to potentially enhance creativity, energy, emotional balance, problem-solving abilities, and to address anxiety, depression, and addiction. This practice has gained popularity in the 21st century.

<span class="mw-page-title-main">Magic truffle</span> Hallucinogenic mushroom preparation

Magic truffles are the sclerotia of psilocybin mushrooms that are not technically the same as "mushrooms". They are masses of mycelium that contain the fruiting body which contains the hallucinogenic chemicals psilocybin and psilocin.

<span class="mw-page-title-main">Psilocybin therapy</span> Experimental use of psilocybin to treat anxiety & depression

Psilocybin therapy is the use of psilocybin in treating a range of mental health conditions, such as depression, anxiety, addictions, obsessive compulsive disorder, and psychosis. It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug. As of 2022, psilocybin is the most commonly researched psychedelic due to its safety and low potential for abuse and dependence. Clinical trials are being conducted at universities and there is evidence confirming the use of psilocybin in the treatment of depression, PTSD and end of life anxiety.

Entheogenic drugs have been used by various groups for thousands of years. There are numerous historical reports as well as modern, contemporary reports of indigenous groups using entheogens, chemical substances used in a religious, shamanic, or spiritual context.

Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action.

California Sober is a recovery model that incorporates the use of psychedelic therapy, along with meditation and exercise, with the intent of abstaining from more harmful and addictive substances. The difference between the California Sober and traditional recovery systems, such as Narcotics Anonymous, is that it doesn't require Asceticism, allowing the practitioner to use substances with little to no potential for addiction in a way that those substances are said to aid in the recovery process.

References

  1. 1 2 3 4 "Robin Carhart-Harris: Profile". The Conversation. 2 July 2014. Retrieved 17 August 2023.
  2. Huberman, Andrew (22 May 2023). "Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health". Huberman Lab. Retrieved 19 August 2023.
  3. Yakowicz, Will (19 November 2021). "Inside The Race To Create A Two-Hour Psychedelic Therapy Experience". Forbes. Retrieved 19 August 2023.
  4. Humphreys, Rachel (17 October 2021). "Ecstasy, LSD and magic mushrooms: are these drugs the future of therapy?". The Guardian. Retrieved 17 August 2023.
  5. 1 2 Franklin-Wallis, Oliver (23 May 2020). "From pandemics to cancer: the science power list". The Times. Retrieved 19 August 2023.
  6. 1 2 "TIME 100 Next: Robin Carhart-Harris". TIME. Retrieved 19 August 2023.
  7. 1 2 3 4 Phelan, Laurence (17 August 2014). "Dr Robin Carhart-Harris is the first scientist in over 40 years to test LSD on humans - and you're next". The Independent. Retrieved 19 August 2023.
  8. 1 2 3 4 Carhart-Harris, Robin (March 2021). "Robin Lester Carhart-Harris: Curriculum Vitae" (PDF). Retrieved 19 August 2023.
  9. 1 2 "Esalen: Faculty: Robin Carhart-Harris, Ph.D". Esalen Institute. Retrieved 20 August 2023.
  10. "The Beckley/Imperial Psychedelic Research Programme". The Beckley Foundation. Retrieved 20 August 2023.
  11. "Robin Carhart-Harris on X". Twitter.com. November 2023.
  12. Carhart-Harris, Robin (20 July 2020). "BNPA Abstracts 2020: Robin Carhart-Harris". Journal of Neurology, Neurosurgery & Psychiatry. British Medical Journal. 91 (8): e2. doi:10.1136/jnnp-2020-BNPA.4 . Retrieved 20 August 2023.
  13. Mangan, Lucy (19 May 2021). "The Psychedelic Drug Trial review – a mind-bending magic mushroom mission". The Guardian. Retrieved 20 August 2023.
  14. Jones, Alexandra (13 March 2021). "'The ketamine blew my mind': can psychedelics cure addiction and depression?". The Guardian. Retrieved 19 August 2023.
  15. Sample, Ian (11 April 2016). "LSD's impact on the brain revealed in groundbreaking images". The Guardian. Retrieved 20 August 2023.
  16. Adams, Ben (May 18, 2016). "'Magic mushroom' compound safe for broader tests in depression". Fierce Biotech.
  17. O'Hare, Ryan (26 April 2019). "Imperial launches world's first Centre for Psychedelics Research". Imperial College London. Retrieved 14 November 2023.
  18. "New $6.4M research program to advance psychedelics research and treatments Grant and Award Announcement". Eurekalert. American Association for the Advancement of Science. 30 March 2021. Retrieved 19 August 2023.
  19. Ponieman, Natan (21 January 2022). "New Coalition Seeks To Reschedule 'Magic Mushrooms' Under International Law". Forbes. Retrieved 2 September 2023.
  20. Seaton Jefferson, Robin (31 January 2019). "Scientists Rethink Psychedelics As Attitudes Change Toward Formerly Illicit Drugs". Forbes. Retrieved 1 September 2023.
  21. Cumming, Ed (26 April 2015). "Is LSD about to return to polite society?". The Guardian. Retrieved 1 September 2023.
  22. Carhart-Harris, Robin (20 April 2021). "Psychedelics are transforming the way we understand depression and its treatment". The Guardian. Retrieved 19 August 2023.
  23. Massey, Nina (4 April 2023). "Psychedelic drug improves symptoms of depression for six months -- study; Dimethyltryptamine is a powerful hallucinogenic found in several plants and can be smoked, snorted or mixed with ayahuasca". The Independent.
  24. "Scientists treat depression with magic mushroom that can 'reboot' the brain". The Herald (Glasgow). 13 October 2017. Retrieved 19 August 2023.
  25. "The Psychedelic Drug Trial". BBC Two. BBC. 8 June 2021. Retrieved 20 August 2023.
  26. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R; et al. (2021). "Trial of Psilocybin versus Escitalopram for Depression". N Engl J Med. 384 (15): 1402–1411. doi: 10.1056/NEJMoa2032994 . PMID   33852780.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. Pollan, Michael (2 February 2015). "The Trip Treatment". The New Yorker. Retrieved 18 November 2023.
  28. Carhart-Harris, Robin (1 January 2021). "Big pharma is about to tune in to the potential of psychedelics". Wired. Retrieved 19 August 2023.
  29. Davison, Nicola (12 May 2018). "The struggle to turn psychedelics into life-changing treatments". Wired. Retrieved 2 September 2023.
  30. 1 2 Goldhill, Olivia (3 July 2023). "As psychedelics near approval, there's no consensus on how they work". Stat. Retrieved 11 January 2024.
  31. 1 2 Carhart-Harris RL (2019). "How do psychedelics work?". Curr Opin Psychiatry. 32 (1): 16–21. doi:10.1097/YCO.0000000000000467. PMID   30394903.
  32. "Psychopharmacology Award 2015: Robin Carhart-Harris" (PDF). British Association for Psychopharmacology. Retrieved 19 November 2023.
  33. "Vox Releases Second Annual Future Perfect 50 List Honoring Visionary Change Agents". Vox. 29 November 2023. Retrieved 7 January 2024.
  34. "Dr. Robin Carhart-Harris Joins Osmind as a Scientific Advisor". Contify Life Science News. 4 February 2021. Retrieved 19 August 2023.
  35. "Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board". Financial News Releases. 2 February 2021. Retrieved 19 August 2023.
  36. Nutt, David; Erritzoe, David; Carhart-Harris, Robin (April 2020). "Psychedelic Psychiatry's Brave New World". Cell. 181 (1): 24–28. doi:10.1016/j.cell.2020.03.020. ISSN   0092-8674. PMID   32243793. Robin Carhart-Harris is a scientific advisor to COMPASS Pathways, Usona Institute, Synthesis Institute, and Entheon Biomedical.
  37. Carhart-Harris, Robin (6 September 2023). ""And there completes one of the most intense..."". X.com. Retrieved 11 January 2024. but turning 43 as of last week and having 2 young children of an almost identical age